Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
C4 Therapeutics (CCCC) Stock Price & Analysis
390 Followers
CCCC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.06 - $11.88
Previous Close$6.45
Volume456.60K
Average Volume (3M)2.25M
Market Cap
$471.32M
Enterprise Value$261.09M
Total Cash (Recent Filing)$253.68M
Total Debt (Recent Filing)$70.98M
Price to Earnings (P/E)-2.7
Beta2.80
Next Earnings
Aug 07, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.37
Shares Outstanding68,600,669
10 Day Avg. Volume1,264,769
30 Day Avg. Volume2,246,823
Standard Deviation0.46
R-Squared0.13
Alpha-0.00620
Financial Highlights & Ratios
Price to Book (P/B)1.89
Price to Sales (P/S)21.32
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.58
Enterprise Value/Gross Profit12.58
Enterprise Value/Ebitda-3.85
Forecast
1Y Price Target
$12.43Price Target Upside81.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
C4 Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentCFT7455 shows promising early results in treating multiple myeloma with high activity observed even at low doses, potentially improving outcomes for heavily treated patients.
Financial HealthWith an upfront payment of $16M from a recent collaboration, C4 Therapeutics' balance sheet is further strengthened, extending its financial stability and funding for clinical developments.
Strategic PartnershipsC4 Therapeutics' partnership with Merck KGaA, which includes potential milestone payments up to $740M, not only validates its technology platform but also presents significant future revenue opportunities.
Bears Say
Clinical Data ConcernsData readout had small patient populations, which raises questions about the reliability of the efficacy and safety profiles.
Development SkepticismInitial skepticism due to previous inability to find a therapeutic index suggests that further development could be value-destructive.
Drug EfficacyCFT7455 monotherapy efficacy still wasn't great, leading to concerns about its potential market success.
---
Ownership Overview
9.79% Insiders
23.55% Mutual Funds
22.76% Other Institutional Investors
43.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.06 and its highest was $11.88 in the past 12 months.
What is C4 Therapeutics’s market cap?
Currently, no data Available
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 90 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on May 08, 2024. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$0.045.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -$0.38.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 68,805,786 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went down -5.007%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Among the largest hedge funds holding C4 Therapeutics’s share is RA Capital Management. It holds C4 Therapeutics’s shares valued at 28M.
---
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.43 (81.46% Upside)
$12.43 (81.46% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.69%
12-Months-Change
Fundamentals
Return on Equity
-48.42%
Trailing 12-Months
Asset Growth
0.59%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
---
CCCC Stock 12 Month Forecast
Average Price Target
$12.43
▲(81.46% Upside)
Technical Analysis
Best Analysts Covering CCCC
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
+20.82%
reiterated a buy rating 3 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +20.82% per trade.
---